Cancer Cell | Efficacy and Biomarker Study of Dual EGFR and BRAFV600E Targeting Combined with PD-1 Inhibitor in Microsatellite Stable Colorectal Cancer

This study provides a novel triplet therapeutic strategy for microsatellite stable, BRAFV600E-mutant metastatic colorectal cancer, suggesting that intervention in the EGFR and MAPK pathways can enhance the efficacy of anti-PD-1 therapy, offering important insights for designing combination regimens in immunotherapy-resistant solid tumors.

 

Literature Overview

The article titled 'Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable, BRAFV600E metastatic colorectal cancer,' published in the journal Cancer Cell, systematically investigates the safety and efficacy of a triplet regimen combining encorafenib (a BRAF inhibitor), cetuximab (an anti-EGFR antibody), and nivolumab (an anti-PD-1 antibody) in patients with microsatellite stable (MSS), BRAFV600E-mutant metastatic colorectal cancer (mCRC). By integrating multi-omics analyses of tissue and liquid biopsies, the study identifies key molecular features predictive of treatment response, providing biomarker evidence for precision immuno-combination therapies.

Background Knowledge

1. Clinical challenge addressed: MSS BRAFV600E mCRC is highly aggressive, responds poorly to conventional chemotherapy, and lacks effective immunotherapies, resulting in extremely poor prognosis and an urgent need for breakthrough therapeutic strategies.
2. Current research bottleneck in BRAFV600E: Although BRAF inhibitors combined with EGFR blockade significantly improve survival, efficacy remains limited, and predictive biomarkers for patient stratification are lacking. Moreover, MSS CRC generally does not respond to PD-1 monotherapy, making the conversion from 'cold' to 'hot' tumors a key challenge.
3. Rationale for the study: Given that BRAFV600E MSS-CRC exhibits higher baseline immune activation, the authors hypothesize that inhibition of the MAPK pathway may enhance tumor immunogenicity and thereby sensitize tumors to anti-PD-1 therapy. Thus, exploring the synergistic effects of triple blockade targeting EGFR, BRAF, and PD-1, along with associated molecular pathways, forms the core logic of the study.

 

 

Research Methods and Experiments

The study employed a single-center, non-randomized phase I/II clinical trial design (NCT04017650), enrolling 26 patients with MSS, BRAFV600E-mutant mCRC who received the triplet therapy of encorafenib, cetuximab, and nivolumab. Efficacy endpoints including ORR, PFS, and OS were assessed radiologically, with systematic collection of pre- and post-treatment tissue and plasma samples. Bulk RNA-seq was used to analyze tumor transcriptomes, complemented by ex vivo tumor tissue slice (E-slice) drug sensitivity assays to validate drug effects. Innovatively, extracellular vesicle RNA (evRNA) from plasma was utilized for dynamic monitoring to evaluate its potential as a non-invasive biomarker. Pathway differences between responders and non-responders were systematically dissected using GSVA, GSEA, and deconvolution analyses.

Key Conclusions and Perspectives

• The triplet regimen achieved a 50% ORR and a median PFS of 7.4 months, significantly outperforming historical controls of encorafenib plus cetuximab, indicating that adding a PD-1 inhibitor substantially improves efficacy.
• Responders showed significant enrichment of p38 MAPK and immune activation signals (e.g., T cells, NK cells) in tumor tissues, whereas non-responders exhibited activation of canonical RAF and metabolic pathways (e.g., amino acid, lipid metabolism), suggesting that the state of MAPK signaling branches influences treatment response.
• In non-responders, complement system and coagulation cascade pathways were significantly activated, correlating with an immunosuppressive microenvironment, potentially representing a novel resistance mechanism, thus implicating the complement pathway as a potential therapeutic target.
• evRNA analysis strongly correlated with tissue findings, and responders showed decreased MAPK signaling and increased IFN-γ response post-treatment, demonstrating that dynamic evRNA monitoring can reflect treatment response in real time, supporting its development as a liquid biopsy biomarker.

Research Significance and Prospects

This study provides clear direction for drug development: future strategies could target the p38-MAPK and complement pathways to enhance the efficacy of the triplet regimen. For clinical monitoring, evRNA technology holds promise for non-invasive, dynamic assessment of treatment response, advancing precision oncology. Regarding disease modeling, the study supports the development of genetically engineered mouse models harboring BRAFV600E and MSS features to further validate the triplet mechanism and screen new combinations.

 

 

Conclusion

This study establishes significant clinical activity of the encorafenib, cetuximab, and nivolumab triplet regimen in MSS, BRAFV600E-mutant mCRC, challenging the traditional notion that these patients do not respond to immunotherapy. By integrating multi-omics analyses of tissue and liquid biopsies, the research not only reveals p38 MAPK activation and an 'hot' immune microenvironment as predictive biomarkers of response but also, for the first time, identifies complement system activation as a potential mediator of resistance, providing critical clues for subsequent mechanistic studies and optimization of combination strategies. From bench to bedside, this study introduces a new paradigm into the precision treatment framework for colorectal cancer, emphasizing the necessity of molecular subtype-guided immuno-combination therapies, with the potential to significantly improve long-term outcomes in this high-risk population and drive a profound shift from one-size-fits-all to personalized treatment.

 

Van K Morris, Christine M Parseghian, Vahid Bahrambeigi, Kyuson Yun, and Scott Kopetz. Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable, BRAFV600E metastatic colorectal cancer. Cancer cell.